Adjuvant treatments in melanoma
For decades, interferon-alpha (IFN-α) has been the only option in the adjuvant treatment of high-risk melanoma. Despite numerous clinical trials and meta-analyzes, IFN-α is not yet a gold standard. It indeed showed benefit in progressionfree survival (PFS) and to a lesser extent in overall survival...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University Hospital for Tumors
2021-01-01
|
| Series: | Libri Oncologici |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/389033 |